drugset / Trial / NCT07428525
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
Timeline
- Start
- 2025-03-14
- Primary completion
- 2026-02-26
- Completion
- 2026-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |
Indications
No indication recorded.